In addition, the use of ACEI/ARB drugs increases the level of ACE2, as well as the wide distribution of ACE2 in pancreas, lung, kidney, heart, and vascular endothelium, which may be an important cause of poor prognosis in patients with COVID-19 and diabetes mellitus. This evidence concerns the gene ACE2 and COVID-19.